Home・Akciju saraksts・Geron Corp

Geron Corp

Atvērts

SektorsVeselības aprūpe

1.61 20.15

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.34

Max

1.6099999999999999

Galvenie mērījumi
By Trading Economics
Ienākumi	25M -3.6M
Pārdošana	3.8M 52M
EPS	-0.005
Peļņas marža	-7.026
Darbinieki	258
EBITDA	27M 3.8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+198.51% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-185M 821M
Iepriekšējā atvēršanas cena	-18.54
Iepriekšējā slēgšanas cena	1.61

Ziņu noskaņojums

By Acuity

20%

80%

55 / 340 Rangs Healthcare

Geron Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. aug. 23:36 UTC

Geron Corp shares are lower in after-market trading, nearing the bottom of their one-month range and below the 20-day moving average.

2026. g. 3. aug. 23:06 UTC

Geron Corp shares are lower in after-market hours, continuing a steady decline since Monday's close and remaining below the 20-day moving average.

2026. g. 31. jūl. 20:02 UTC

Geron Corp shares are lower as the Biotechnology sub-sector declines. The stock pulled back from an earlier session high, finishing below its 20-day moving average.

2026. g. 30. jūl. 20:56 UTC

Geron Corp shares are higher in after-market hours, influenced by positive corporate earnings amid broader market uncertainty following the Federal Reserve's interest rate decision.

2026. g. 29. jūl. 19:32 UTC

Macro Event

Geron Corp shares are lower as market volatility rises following the Federal Reserve's interest rate decision amid ongoing economic growth and inflation concerns.

2026. g. 28. jūl. 18:51 UTC

Shares of Geron Corp are lower today amid broader market volatility and uncertainty regarding Federal Reserve decisions. The stock declined since Monday's close.

2026. g. 27. jūl. 23:16 UTC

Geron Corp shares are lower in after-market trading, despite earlier gains, with no specific company news driving the decline.

2026. g. 24. jūl. 19:46 UTC

Geron Corp shares are lower in Friday's session amid broader market volatility and uncertainty from fluctuating oil prices and new U.S. tariffs.

2026. g. 23. jūl. 10:11 UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

2026. g. 22. jūl. 18:51 UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

2026. g. 21. jūl. 23:41 UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

2026. g. 20. jūl. 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Salīdzinājums

Cenas izmaiņa

Geron Corp Prognoze

Cenas mērķis

By TipRanks

198.51% augšup

Prognoze 12 mēnešiem

Vidējais 4 USD 198.51%

Augstākais 5 USD

Zemākais 3 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Geron Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Geron Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

55 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.